FOSCARNET SODIUM ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO5P.3Na
Molecular Weight	191.9508
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O

InChI

InChIKey=DFHAXXVZCFXGOQ-UHFFFAOYSA-K

InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3

HIDE SMILES / InChI

Molecular Formula	CO5P
Molecular Weight	122.9815
Charge	-3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf | https://www.drugs.com/cdi/foscarnet.html

Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic pyrophosphate that inhibits replication of herpesviruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virusspecific DNA polymerases at concentrations that do not affect cellular DNA polymerases. FOSCAVIR does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to FOSCAVIR.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Human herpesvirus 1 DNA polymerase 24 Target ID: CHEMBL1872 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/6298425 \| https://www.ncbi.nlm.nih.gov/pubmed/15673740	Inhibitor 8504
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7524439 \| https://www.ncbi.nlm.nih.gov/pubmed/9240351	Inhibitor 8504	2.03 µM [IC50]
Human herpesvirus 5 DNA polymerase 13 Target ID: CHEMBL3414 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16134946	Inhibitor 8504	2.5 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cytomegalovirus retinitis 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf	Primary		Approved 8583	FOSCAVIR Approved Use INDICATIONS CMV Retinitis FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. Launch Date 1991

C_max

Value	Dose	Analyte	Population
46.4 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
86.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
78.7 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
64.9 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
86.4 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
887.3 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
589 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
623 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
300 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
646 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
688 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
494 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
826 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3308 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:		FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:		FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2400 ug 2 times / week multiple, intravitreal Highest studied dose Dose: 2400 ug, 2 times / week Route: intravitreal Route: multiple Dose: 2400 ug, 2 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/	unhealthy, 36.6 Health Status: unhealthy Age Group: 36.6 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/	Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/
5.45 g 2 times / day multiple, intravenous Overdose Dose: 5.45 g, 2 times / day Route: intravenous Route: multiple Dose: 5.45 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Other AEs: Impaired renal function... Other AEs: Impaired renal function (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
6.25 g 2 times / day multiple, intravenous Overdose Dose: 6.25 g, 2 times / day Route: intravenous Route: multiple Dose: 6.25 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Other AEs: Cardio-respiratory arrest... Other AEs: Cardio-respiratory arrest (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	Disc. AE: Impaired renal function, Hematuria... AEs leading to discontinuation/dose reduction: Impaired renal function Hematuria Cerebral hemorrhage Physical impairment Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/

AEs

AE	Significance	Dose	Population
Impaired renal function	grade 5	5.45 g 2 times / day multiple, intravenous Overdose Dose: 5.45 g, 2 times / day Route: intravenous Route: multiple Dose: 5.45 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
Cardio-respiratory arrest	grade 5	6.25 g 2 times / day multiple, intravenous Overdose Dose: 6.25 g, 2 times / day Route: intravenous Route: multiple Dose: 6.25 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
Cerebral hemorrhage	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Hematuria	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Impaired renal function	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Physical impairment	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 303 UGT 219 OAT1 395

Drug as victim

Target	Modality	Activity
CYP 303	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/7527325/	no
OAT1 395	substrate 4014 Sources: https://jpet.aspetjournals.org/content/294/3/844	no
UGT 219	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/7527325/	no

PubMed

Title	Date	PubMed
[Therapeutic effect of gefin, a new antiviral drug, in experimental genital herpes ].	2002-02-21	11852781
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.	2002-02-15	11830461
Drugs for non-HIV viral infections.	2002-02-04	11828264
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.	2002-02-01	11807018
Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients.	2002-02-01	11774077
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.	2002-02	11809865
T-cell activation response to allogeneic CMV-infected endothelial cells is not prevented by ganciclovir or foscarnet: implications for transplant vascular sclerosis.	2002-01-27	11821754
[In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?].	2002-01	11820977
Viral diseases of the skin: diagnosis and antiviral treatment.	2002	11817982
Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations.	2002	11785848
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.	2001-12-21	11581260
Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.	2001-12-18	11747000
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].	2001-12	11844451
Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.	2001-12	11844151
Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia.	2001-12	11794704
Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.	2001-12	11733458
Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.	2001-12	11595579
Separation methods for antiviral phosphorus-containing drugs.	2001-11-25	11817037
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.	2001-11-22	11708913
Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.	2001-11-01	11577375
[Cytomegalovirus infection].	2001-11	11808108
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.	2001-11	11781649
Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum.	2001-11	11734722
Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.	2001-11	11734717
Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo.	2001-11	11602788
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.	2001-10	11781635
Cytomegalovirus infection: the point in 2001.	2001-10	11737406
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.	2001-10	11704795
Vascular calcification and inorganic phosphate.	2001-10	11576919
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.	2001-10	11533171
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.	2001-09-01	11547769
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.	2001-09-01	11547768
Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.	2001-09	11642018
Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats.	2001-09	11509741
Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein.	2001-09	11505446
[Anti-hepatitis B virus effects of lamivudine and other five drugs in vitro].	2001-08-25	11718074
The potency of acyclovir can be markedly different in different cell types.	2001-08-03	11521752
Chemoselectivity in metal cation mediated hydrolysis of a phosphonoformate diester.	2001-08-01	11472191
[Cytomegalovirus enteritis in recipients of allogeneic peripheral blood stem cell transplantation].	2001-08	11718057
Cytomegalovirus treatment options in immunocompromised patients.	2001-08	11584992
Infections after stem cell transplantation in children: state of the art and recommendations.	2001-08	11571529
Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.	2001-08	11535994
Generation of hydroxyl radicals by the antiviral compound phosphonoformic acid (foscarnet).	2001-07	11484910
[In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].	2001-06	11704769
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.	2001-06	11551024
[Varicella pneumonia in the adult. Study of 9 cases].	2001-06	11503578
Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication.	2001	11789588
Current and potential therapies for the treatment of herpesvirus infections.	2001	11548208
[Current aspects of chemotherapy of sexually transmitted viral diseases].	2001	11496763
Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS.	2001	11465299

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for CMV Retinitis Induction therapy: 90 mg/kg IV (90- to 120-minute infusion) every 12 hours or 60 mg/kg IV (minimum 1-hour infusion) every 8 hours over 2 to 3 weeks depending on clinical response Maintenance therapy: 90 to 120 mg/kg IV (2-hour infusion) once a day Usual Adult Dose for Herpes Simplex - Mucocutaneous/Immunocompromised Host Induction therapy: 40 mg/kg IV (minimum 1-hour infusion) every 8 or 12 hours Duration of therapy: 2 to 3 weeks or until healed Usual Adult Dose for CMV Gastroenteritis US CDC, NIH, and IDSA recommendations for the treatment of CMV esophagitis or colitis in HIV-infected patients: 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours

Route of Administration: Intravenous

In Vitro Use Guide

Foscarnet inhibits in vitro the replication of all herpes viruses, including human cytomegalovirus (HCMV) at concentrations of 100 to 300 umol/l and has a dose-related inhibitory effect on HIV-1 virus, influenza virus and hepatitis B virus.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:16:41 GMT 2025` Edited by `admin` on `Mon Mar 31 19:16:41 GMT 2025`
Record UNII	8C5OQ81LWT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOSCARNET SODIUM ANHYDROUS

Common Name

English

A-29622

Preferred Name

English

foscarnet sodium [INN]

Common Name

English

Foscarnet sodium [WHO-DD]

Common Name

English

NSC-758148

Code

English

PHOSPHONOFORMIC ACID, TRISODIUM SALT

Common Name

English

FOSCARNET SODIUM [MI]

Common Name

English

PHOSPHINECARBOXYLIC ACID, 1,1-DIHYDROXY-, 1-OXIDE, SODIUM SALT (1:3)

Common Name

English

TRISODIUM PHOSPHONOFORMATE

Systematic Name

English

NSC-313410

Code

English

PHOSPHINECARBOXYLIC ACID, DIHYDROXY-, OXIDE, TRISODIUM SALT

Common Name

English

PHOSPHONOFORMIC ACID TRISODIUM SALT

Common Name

English

Code System Code Type Description

CAS

63585-09-1